Archive for June, 2013

U.S. residents today are living longer than previous generations, thanks to improved public health and medical treatment. But they’re also living longer with chronic geriatric health conditions like dementia, urinary incontinence, depression and debilitating falls, which often require complex medical care… Read & Research Alzheimer’s More

Be the first to comment

Building on research published eight years ago in the journal Chemistry and Biology, Kenneth S… Read & Research Alzheimer’s More

Be the first to comment

UCLA researchers have found that older adults who regularly used a brain-fitness program on a computer demonstrated significantly improved memory and language skills. The UCLA team studied 69 dementia-free participants, with an average age of 82, who were recruited from retirement communities in Southern California… Read & Research Alzheimer’s More

Be the first to comment

A new class of experimental drug-like small molecules is showing great promise in targeting a brain enzyme to prevent early memory loss in Alzheimer’s disease, according to Northwestern Medicine® research. Developed in the laboratory of D. Martin Watterson, the molecules halted memory loss and fixed damaged communication among brain cells Read & Research Alzheimer’s More

Be the first to comment

Researchers at Columbia University Medical Center (CUMC) have demonstrated that a protein called caspase-2 is a key regulator of a signaling pathway that leads to cognitive decline in Alzheimer’s disease. The findings, made in a mouse model of Alzheimer’s, suggest that inhibiting this protein could prevent the neuronal damage and Read & Research Alzheimer’s More

Be the first to comment

By Letizia Polito, Patrick G. Kehoe, Annalisa Davin, Luisa Benussi, Roberta Ghidoni, Giuliano Binetti, Pierluigi Quadri, Ugo Lucca, Mauro Tettamanti, Francesca Clerici, Silvia Bagnoli, Daniela Galimberti, Benedetta Nacmias, Sandro Sorbi, Antonio Guaita, Elio Scarpini, Claudio Mariani, Gianluigi Forloni, Diego Albani Abstract: Background: Human sirtuins are a current hotspot for research in neurodegenerative disorders, including Alzheimer’s disease (AD). This study investigated whether genetic variants in two members of the sirtuin family, SIRT2 and SIRT3, affected AD susceptibility.Methods: A genetic case–control study was performed, comprising 534 probable AD cases and 638 nondemented control Read & Research Alzheimer’s More

Be the first to comment

By Monika Karczewska-Kupczewska, Natalia Lelental, Agnieszka Adamska, Agnieszka Nikołajuk, Irina Kowalska, Maria Górska, Rüdiger Zimmermann, Johannes Kornhuber, Marek Strączkowski, Piotr Lewczuk Abstract: Background: Accumulating body of evidence suggests pathophysiologic links between Alzheimer’s disease and diabetes mellitus (DM). For example, the two crucial peptides playing a role in both degenerative disorders, amyloid β (Aβ) and insulin, are metabolized by the same enzyme, insulin degrading enzyme. Euglycemic hyperinsulinemic clamp is a method of Read & Research Alzheimer’s More

Be the first to comment

By Amalia Tsolakidou, Panagiotis Alexopoulos, Liang-Hao Guo, Timo Grimmer, Christine Westerteicher, Martina Kratzer, Meizi Jiang, Hideaki Bujo, Francesco Roselli, Maria Rosaria Leante, Paolo Livrea, Alexander Kurz, Robert Perneczky Abstract: Background: β-Site amyloid precursor protein (APP)–cleaving enzyme 1 (BACE1) activity determines the rate of APP cleavage and is therefore the main driver of amyloid β production, which is a pathological hallmark of Alzheimer’s disease (AD).Methods: The present study explored the correlation between BACE1 activity and cerebrospinal fluid (CSF) markers Read & Research Alzheimer’s More

Be the first to comment

By William R. Shankle, Junko Hara, Tushar Mangrola, Suzanne Hendrix, Gus Alva, Michael D. Lee Abstract: Identifying disease-modifying treatment effects in earlier stages of Alzheimer’s disease (AD)—when changes are subtle—will require improved trial design and more sensitive analytical methods. We applied hierarchical Bayesian analysis with cognitive processing (HBCP) models to the Alzheimer’s Disease Assessment Scale—Cognitive subscale (ADAS-Cog) and MCI (mild cognitive impairment) Screen word list Read & Research Alzheimer’s More

Be the first to comment

By Julien Dumurgier, Olivier Vercruysse, Claire Paquet, Stéphanie Bombois, Chloé Chaulet, Jean-Louis Laplanche, Katell Peoc’h, Susanna Schraen, Florence Pasquier, Jacques Touchon, Jacques Hugon, Sylvain Lehmann, Audrey Gabelle Abstract: Background: The assessment of total tau, phosphorylated tau (pTau-181) and amyloid beta (Aβ 1–42) concentrations in the cerebrospinal fluid (CSF) of subjects has been validated for the diagnosis of Alzheimer’s disease (AD). Although these measurements have shown some variability, little is known about their intersite variability in clinical settings.Methods: Read & Research Alzheimer’s More

Be the first to comment

By Anders Wimo, Anders Gustavsson, Linus Jönsson, Bengt Winblad, Ming-Ann Hsu, Brenda Gannon Abstract: Background: The Resource Utilization in Dementia (RUD) questionnaire is the most widely used instrument for resource use data collection in dementia, enabling comparison of costs of care across countries with differing health care provisions. Recent feedback from payers questioned its face validity given that health care provisions have changed Read & Research Alzheimer’s More

Be the first to comment

By Henrik Zetterberg, Kaj Blennow Abstract: Certain preparations of Alzheimer-associated amyloid beta (Aβ) exhibit rapid (within minutes) synaptotoxicity when applied to hippocampal slices or neuronal cell cultures, or when injected into the central nervous system of rodents. In addition, it is well known that some elderly people have brain amyloidosis without showing signs of cognitive Read & Research Alzheimer’s More

Be the first to comment

By Gisela Pusswald, Doris Moser, Andreas Gleiß, Stefan Janzek-Hawlat, Eduard Auff, Peter Dal-Bianco, Johann Lehrner Abstract: Background: Early detection of dementia is becoming more and more important owing to the advent of pharmacologic treatment.Objective: The goals of this study were to establish prevalence of mild cognitive impairment (MCI) subtypes in an outpatient memory clinic cohort using two different modes of MCI determination.Design: Consecutive patients complaining Read & Research Alzheimer’s More

Be the first to comment

By Rik Ossenkoppele, Niels D. Prins, Yolande A.L. Pijnenburg, Afina W. Lemstra, Wiesje M. van der Flier, Sofie F. Adriaanse, Albert D. Windhorst, Ron L.H. Handels, Claire A.G. Wolfs, Pauline Aalten, Frans R.J. Verhey, Marcel M. Verbeek, Mark A. van Buchem, Otto S. Hoekstra, Adriaan A. Lammertsma, Philip Scheltens, Bart N.M. van Berckel Abstract: Background: [11C]Pittsburgh compound B ([11C]PIB) and [18F]-2-fluoro-2-deoxy-D-glucose ([18F]FDG) PET measure fibrillar amyloid-β load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population.Methods: One hundred fifty-four patients underwent paired dynamic [11C]PIB and static [18F]FDG PET scans shortly after completing Read & Research Alzheimer’s More

Be the first to comment

By Xueya Cai, Noll Campbell, Babar Khan, Christopher Callahan, Malaz Boustani Abstract: Background: Older Americans are facing an epidemic of chronic diseases and are thus exposed to anticholinergics (ACs) that might negatively affect their risk of developing mild cognitive impairment (MCI) or dementia.Objective: To investigate the association between impairment in cognitive function and previous AC exposure.Design: A retrospective cohort study.Setting: Primary Read & Research Alzheimer’s More

Be the first to comment

By Sebastian J. Crutch, Jonathan M. Schott, Gil D. Rabinovici, Bradley F. Boeve, Stefano F. Cappa, Bradford C. Dickerson, Bruno Dubois, Neill R. Graff-Radford, Pierre Krolak-Salmon, Manja Lehmann, Mario F. Mendez, Yolande Pijnenburg, Natalie S. Ryan, Philip Scheltens, Tim Shakespeare, David F. Tang-Wai, Wiesje M. van der Flier, Lisa Bain, Maria C. Carrillo, Nick C. Fox Abstract: Posterior cortical atrophy (PCA) is a clinicoradiologic syndrome characterized by progressive decline in visual processing skills, relatively intact memory and language in the early stages, and atrophy of posterior brain regions. Misdiagnosis of PCA is common, owing not only to its relative rarity and unusual and variable presentation, but Read & Research Alzheimer’s More

Be the first to comment

By Kurt A. Jellinger In a recent article, Crutch and colleagues commented on posterior cortical atrophy (PCA) as a clinical–radiological syndrome characterized by progressive decline in visual processing skills, relatively intact memory and language during the early stages, and atrophy of the posterior brain regions, which is frequently considered an atypical or visual Read & Research Alzheimer’s More

Be the first to comment

By Keith A. Johnson, Satoshi Minoshima, Nicolaas I. Bohnen, Kevin J. Donohoe, Norman L. Foster, Peter Herscovitch, Jason H. Karlawish, Christopher C. Rowe, Saima Hedrick, Virginia Pappas, Maria C. Carrillo, Dean M. Hartley Abstract: Amyloid PET imaging is a novel diagnostic test that can detect in living humans one of the two defining pathologic lesions of Alzheimer disease, amyloid-β deposition in the brain. The Amyloid Imaging Task Force of the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging previously published appropriate Read & Research Alzheimer’s More

Be the first to comment

Subscriber information"> Subscriber information

Posted June 27, 2013 By FuckAlzheimers

Read & Research Alzheimer’s More

Be the first to comment

By Maria C. Carrillo, Bruno Vellas Results of recent Alzheimer’s disease (AD) clinical trials have been mixed. Both the bapineuzumab and solanezumab trials did not reach planned end points, although prespecified subgroup and pooled analyses of results in participants with mild AD given solanezumab demonstrated signs of efficacy. Despite these results, there is much to learn Read & Research Alzheimer’s More

Be the first to comment

By Michael W. Weiner, Karl E. Friedl, Anthony Pacifico, Julie C. Chapman, Michael S. Jaffee, Deborah M. Little, Geoffrey T. Manley, Ann McKee, Ronald C. Petersen, Roger K. Pitman, Kristine Yaffe, Henrik Zetterberg, Robert Obana, Lisa J. Bain, Maria C. Carrillo Abstract: Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are signature injuries of the wars in Iraq and Afghanistan and have been linked to an increased risk of Alzheimer’s disease (AD) and other dementias. A meeting hosted by the Alzheimer’s Association and the Veterans’ Health Research Institute (NCIRE) in Read & Research Alzheimer’s More

Be the first to comment

By Sergio Iván Prada A new set of files are available to researchers as free downloads and they contain nonidentifiable claim-specific information for Fee-for-Service (FFS) Medicare beneficiaries. Data on use and payments per beneficiary for Part A, B, and D are available for Alzheimer’s disorders and 10 other chronic conditions, allowing for novel comparisons. Read & Research Alzheimer’s More

Be the first to comment

Read & Research Alzheimer’s More

Be the first to comment

By Maria C. Carrillo More than 20 years have passed since the publication of the “Five-Five, Ten-Ten Plan for Alzheimer’s Disease” . The editorial represented a watershed moment for the field by calling forward an expanded public health campaign to combat a growing worldwide pandemic due to Alzheimer’s disease (AD). Today, the editorial’s clarion call Read & Research Alzheimer’s More

Be the first to comment

Editorial Board"> Editorial Board

Posted June 27, 2013 By FuckAlzheimers

Read & Research Alzheimer’s More

Be the first to comment

By Bruno Vellas, Maria C. Carrillo, Cristina Sampaio, H. Robert Brashear, Eric Siemers, Harald Hampel, Lon S. Schneider, Michael Weiner, Rachelle Doody, Zaven Khachaturian, Jesse Cedarbaum, Michael Grundman, Karl Broich, Ezio Giacobini, Bruno Dubois, Reisa Sperling, Gordon K. Wilcock, Nick Fox, Philip Scheltens, Jacques Touchon, Suzanne Hendrix, Sandrine Andrieu, Paul Aisen, EU/US/CTAD Task Force Members Abstract: An international task force of investigators from academia, industry, nonprofit foundations, and regulatory agencies met in Monte Carlo, Monaco, on October 31, 2012, to review lessons learned from the recent bapineuzumab and solanezumab trials, and to incorporate insights gained from these trials into future clinical studies. Although there is Read & Research Alzheimer’s More

Be the first to comment

Contents"> Contents

Posted June 27, 2013 By FuckAlzheimers

Read & Research Alzheimer’s More

Be the first to comment

By Karl Herrup, Maria C. Carrillo, Dale Schenk, Angela Cacace, Susan DeSanti, Robert Fremeau, Ratan Bhat, Marcie Glicksman, Patrick May, Russell Swerdlow, Linda J. Van Eldik, Lisa J. Bain, Samantha Budd Abstract: For decades, researchers have focused primarily on a pathway initiated by amyloid beta aggregation, amyloid deposition, and accumulation in the brain as the key mechanism underlying the disease and the most important treatment target. However, evidence increasingly suggests that amyloid is deposited early during the course of disease, even Read & Research Alzheimer’s More

Be the first to comment

By Heather M. Snyder, Lisa J. Bain, Robert Egge, Maria C. Carrillo With the prevalence of dementia expected to exceed 115 million worldwide by 2050 , stakeholders across all sectors of society recognize the need for an aggressive, coordinated, and global response. Similar challenges have been faced in the past and provide models for how to mount an effective response today. In Read & Research Alzheimer’s More

Be the first to comment

Alzheimer's Association Update"> Alzheimer's Association Update

Posted June 27, 2013 By FuckAlzheimers

The 25th annual Alzheimer’s Association Advocacy Forum, held this April in Washington, D.C., attracted a record-breaking 900-plus registrants from every state in the nation. Award-winning actor and honorary chair of the meeting, David Hyde Pierce, opened the proceedings. Pierce, who has been a passionate Alzheimer’s advocate since 1998, Read & Research Alzheimer’s More

Be the first to comment